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BACKGROUND: Kallikrein-related peptidases (KLKs) are a family of serine proteases that have been shown to be dysregulated in several
malignancies including ovarian cancer. The control of kallikrein genes and their physiological function in cancer is not well understood.
We hypothesized that microRNAs (miRNAs) represent a novel mechanism for post-transcriptional control of KLK expression in
cancer.
METHODS: We first analysed miRNA expression in ovarian cancer in silico. A total of 98 miRNAs were reported to have altered
expression in ovarian cancer. Three of these miRNAs were predicted to target KLK10. We experimentally verified the predicted
miR–KLK10 interaction using two independent techniques, a luciferase assay with a construct containing the KLK10 30 untranslated
region (UTR), pMIR–KLK10, and measuring KLK10 protein levels after transfection with miRNA.
RESULTS: When we co-transfected cells with pMIR–KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal,
suggesting that these miRNAs can target KLK10. We then examined the effect of these three miRNAs on KLK10 protein expression
and cell growth. Transfection of all miRNAs, let-7f, miR-224, and miR-516a led to a decrease in protein expression and cellular
growth. This effect was shown to be dose dependent. The KLK10 protein levels were partially restored by co-transfecting let-7f and
its inhibitor. In addition, there was a slight decrease in KLK10 mRNA expression after transfection with let-7f.
CONCLUSIONS: Our results confirm that KLKs can be targeted by more than one miRNA. Increased expression of certain miRNAs in
ovarian cancer can lead to decreased KLK protein expression and subsequently have a negative effect on cell proliferation. This
dose-dependent effect suggests that a ‘tweaking’ or ‘fine-tuning’ mechanism exists in which the expression of one KLK can be
controlled by multiple miRNAs. These data together suggest that miRNA may be used as potential therapeutic options and further
studies are required.
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MicroRNAs (miRNAs) are small RNAs that do not code for
proteins, but function by controlling protein expression of other
genes. MiRNAs have been shown to control cell growth,
differentiation, and apoptosis. Shortly after their discovery,
miRNAs were found to be associated with cancer. Many reports
have documented dysregulation of miRNAs in various malignan-
cies (Calin and Croce, 2006a). Moreover, earlier studies have
shown a tendency of cancer-dysregulated miRNAs to be located in
cancer hotspot chromosomal regions, such as fragile sites, regions
of loss of heterozygosity, amplification, or common breakpoint
regions (Calin and Croce, 2006b). In human beings, most miRNAs
function by imperfect complementarity to the 30 untranslated
region (UTR) of their target mRNAs. Recent evidence has also
shown that miRNAs can also bind outside the 30UTR of their
targets, including the 50UTR and the coding sequence (Lewis et al,
2005; Nakamoto et al, 2005; Miranda et al, 2006; Stark et al, 2007;
Tay et al, 2008).
The association of kallikrein-related peptidases (KLKs) and
cancer is well documented in the literature and many KLKs have
been shown to be dysregulated in different malignancies (Emami
and Diamandis, 2008). Several independent reports have shown
that many KLKs are dysregulated in ovarian cancer. At least seven
kallikrein proteins are up-regulated in ovarian cancer compared
with normal ovarian tissues (Yousef et al, 2003b). The prognostic
value of at least 11 out of 15 members of the human kallikrein
family in ovarian cancer has been also published (Clements et al,
2004; Yousef et al, 2005; Prezas et al, 2006; Dorn et al, 2007). Six
kallikreins, KLK4, KLK5, KLK6, KLK7, KLK10, and KLK15 (Kim
et al, 2001; Kyriakopoulou et al, 2003; Shvartsman et al, 2003;
Yousef et al, 2003c; Kountourakis et al, 2008), are markers of poor
prognosis in ovarian cancer. Two kallikreins, KLK9 (Yousef et al,
2001) and KLK14 (Yousef et al, 2003a), are markers of favourable
prognosis. In addition, KLK8 (Borgono et al, 2006; Kountourakis
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set al, 2009), KLK11 (Borgono et al, 2003; Shigemasa et al, 2004),
and KLK13 (Scorilas et al, 2004; White et al, 2009) have conflicting
evidence on prognosis. A recent report showed a concordant
higher expression of both KLK5 and KLK7 in ovarian carcinomas,
especially late-stage serous carcinomas, compared with normal
ovaries and benign adenomas (Dong et al, 2003). As serine
proteases, the most accepted hypothesis of function of KLKs in
ovarian cancer is to enhance metastasis by extracellular matrix
degradation. Recent reports, however, elucidated other possible
functions of KLKs in controlling cell proliferation (Yousef and
Diamandis, 2002).
Kallikrein-related peptidase 10 is a member of the kallikrein
family that has been shown by numerous reports to be up-
regulated in ovarian cancer (Luo et al, 2001, 2003; Bayani et al,
2008). The KLK10 protein was also purified from ascites fluid of
ovarian cancer patients (Luo et al, 2006). Reports have shown
diagnostic and prognostic uses of KLK10 in ovarian cancer
(Shvartsman et al, 2003), and as such, it represents a possible
therapeutic target for metastatic ovarian cancer.
Kallikrein functions are regulated at various levels, including
transcription, translation, and post-translation (Yousef et al, 2005;
Emami and Diamandis, 2007). A number of mechanisms have been
proposed. Steroid hormones are reported to have a function in
controlling KLK expression, but they, however, cannot be the sole
factor controlling KLK expression in cancer (Yousef and
Diamandis, 2002), as there are relatively short distances between
adjacent kallikrein genes [as short as 1.5kb between KLK1 and
KLK15 (Yousef et al, 2000)], with no classic promoter elements or
hormone response elements. Other possible regulatory mecha-
nisms of kallikrein gene expression are hypermethylation of
CpG islands and modification of the chromatin structure of the
kallikrein locus. This has been reported in breast cancer and
lymphoblastic leukaemia (Pampalakis and Sotiropoulou, 2006).
At the protein level, mechanisms for controlling serine protease
activity include producing kallikreins in an inactive ‘proenzymes’
(or zymogens) that are activated only when necessary. Once
activated, serine proteases are controlled by ubiquitous endo-
genous inhibitors. Another interesting feature is the parallel
co-expression of many KLKs in physiological and pathological
states (Shaw and Diamandis, 2007).
Obvious discrepancies were observed in the expression profiles
of many kallikreins between the mRNA and protein levels, and a
post-transcriptional control mechanism was suggested (Yousef
et al, 2005). MiRNAs represent potential candidates for this
function. This is further supported by the finding that many KLKs
show parallel over-expression in ovarian cancer, raising the
possibility of the existence of other mechanisms that simulta-
neously control expression of groups of kallikreins.
We have recently published the first manuscript of in silico and
experimental-based analysis of the potential of KLK regulation by
miRNAs (Chow et al, 2008). We also provided preliminary
experimental validation of the miRNA target prediction analysis.
In this manuscript, we further test the hypothesis that multiple
miRNAs can target the same KLK transcript and provide evidence
that miRNAs can have a negative effect on cell proliferation
through regulating KLK10 protein expression.
MATERIALS AND METHODS
Bioinformatic analysis
In silico expression and comparative genomic hybridisation
analyses Dysregulated miRNAs in ovarian cancer was compiled
from eight published studies (Iorio et al, 2007; Bearfoot et al, 2008;
Dahiya et al, 2008; Nam et al, 2008; Taylor and Gercel-Taylor, 2008;
Zhang et al, 2008; Boren et al, 2009; Resnick et al, 2009).
Assessment of KLK protein dysregulation in ovarian cancer was
compiled from the results of 17 studies (Dong et al, 2001; Luo et al,
2001, 2003; Tanimoto et al, 2001; Hoffman et al, 2002; Yousef
et al, 2002, 2003b; Borgono et al, 2003; Diamandis et al, 2003;
Ni et al, 2004; Scorilas et al, 2004; Xi et al, 2004; Prezas et al, 2006;
Shan et al, 2007; Bayani et al, 2008; Shaw and Diamandis, 2008).
Chromosomal aberration in ovarian cancer was extracted from the
Progenetix comparative genomic hybridisation database available
as of January 2009 (Baudis and Cleary, 2001). Average genetic
changes from 543 cases of ovarian cancer were used for analysis.
Target prediction analysis Target prediction analyses were
performed using multiple algorithms, including miRanda (John
et al, 2004), PicTar (Rajewsky and Socci, 2004), and TargetScanS
(Lewis et al, 2003). Predictions from different programmes were
compiled using the TargetCombo algorithm (Sethupathy et al,
2006), and the miRecords target prediction programme, which
complies predictions from 11 different algorithms (http://
mirecords.umn.edu/miRecords/prediction_query.php). To achieve
a balanced sensitivity and specificity, only predictions by more
than four programmes (using the miRecords analysis) or those
identified by Optimised Intersection (which includes both PicTar,
TargetScanS) (using TargetCombo analysis) were included in the
study. Optimised intersection is suggested to provide a good
compromise between sensitivity and specificity for gene prediction
programmes. We used the latest versions available of each
programme at the time of the analysis (January 2009).
Total RNA extraction and quantitative RT–PCR
Total RNA extraction was performed with the mirVana extraction
kit, following the manufacturer’s protocol (Ambion, Austin, TX,
USA). The quality of extracted RNA was assessed by electro-
pherogram and gel analysis. Quantitative RT–PCR of miRNA was
performed with the TaqMan miRNA Assay kit according to the
manufacture’s protocol (Applied Biosystems, Foster City, CA,
USA). The miRNA transcripts of three of the miRNAs predicted to
target KLK10, let-7f, miR-224, and miR-516a were first reverse-
transcribed into cDNA using gene-specific primers. This
was followed by real-time PCR amplification using ABI7500
Standard system and miRNA-specific probes in triplicate (Applied
Biosystems). Expression values were normalised to a small
nucleolar RNA, RNU44 (Applied Biosystems), which has been
proven to have consistent expression levels in malignant and
non-malignant tissue pairs (Nikiforova et al, 2008). Ct values were
calculated by the ABI7500. DCt values were calculated using
the Ct values of the miRNA probes and the RNU44 for each
corresponding sample.
Luciferase assay
To experimentally validate the predicted miRNA–KLK10 inter-
actions, we transfected the pMIR-report luciferase construct
(Applied Biosystems) with miRNAs in cell line models. The
predicted target region of the KLK10 30UTR (GenBank accession #
NM_002776) was cloned into the vector using the primer
sequences: forward 50 cccactagtcctggatcaataaagtcatacgc 30, and
reverse 50 tcatgtaaggcttaacacagtggaagcttccc 30 (Operon, Huntsville,
AL, USA) and called pMIR–KLK10.
Transfection of each miRNA was carried out according to the
siPORT NeoFX transfection protocol (Ambion). Transfection
agent/RNA molecules complex formation was carried out in
Opti-MEM Reduced-Serum Media (Gibco, Burlington, Canada.).
Cells were allowed to grow after transfection for 3 days and then
lyzed using lysis buffer (Applied Biosystems). The luciferase and
b-gal activity of the samples were assayed using the Dual-Light
System (Applied Biosystems) according to the manufacture’s
protocol.
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sKLK10 protein assay
The KLK10 protein expression was measured by enzyme-linked
immunosorbent assay as described earlier (Luo et al, 2006; Shaw
and Diamandis, 2007). The KLK10 antibody was first immobilised
on a 96-well white polystyrene plate (200ng per well) by
incubating in coating buffer [50mmoll
–1 Tris and 0.05% sodium
azide (pH 7.8)] overnight at room temperature. The plate was then
washed three times with washing buffer [50mmoll
–1 Tris,
150mmoll
–1 NaCl, and 0.05% Tween 20 (pH 7.8)]. The KLK10
standards or samples were added to each well (100ml per well),
diluted 1:1 in assay buffer [50mmoll
–1 Tris, 6% bovine serum
albumin, 10% goat IgG, 2% mouse IgG, 1% bovine IgG, 0.5moll
–1
KCl, and 0.05% sodium azide (pH 7.8)], incubated for 2h with
shaking, and then washed six times, as above.
Subsequently, biotinylated polyclonal detection KLK10 antibody
was diluted 2000-fold in assay buffer, was added to the plate, and
incubated for 1h. After incubation, the plate was washed as above,
and alkaline phosphatase-conjugated goat anti-rabbit IgG, diluted
2000-fold in assay buffer, was applied and plates were incubated
for 15min. After washing as above, the alkaline phosphatase
substrate diflunisal phosphate in substrate buffer [0.1moll
–1 Tris
(pH 9.1), 0.1moll
–1 NaCl, and 1mmoll
–1 MgCl2] was added to
each well and incubated for 10min followed by addition of
developing solution (1moll
–1 Tris base, 0.4moll
–1 NaOH,
2mmoll
–1 TbCl3, and 3mmoll
–1 EDTA) for 1min. The resultant
fluorescence was measured by time-resolved fluorometry with
the envision time-resolved fluorometer (Perkin-Elmer, Waltham,
USA). The assay covered a linear range of detection of
0.05–10ngml
–1.
Cell growth assay
The ovarian cancer cell line OVCAR-3 was selected for transfection
of KLK10-targeting miRNA to measure the effect on both cell
growth and KLK10 protein expression. Cells were grown in RPMI
media (Gibco, Burlington, CA, USA) supplemented with 10% foetal
bovine serum and 0.01mgml
–1 bovine insulin with 5% CO2 and
371C. The siPORT NeoFX transfection system (Ambion) was used.
Cells were transfected with pre-miR hsa-let-7f, hsa-miR-224,
hsa-miR-516a, and a random sequence as a control. All precursor
molecules (± anti-miR antagonist molecule for each miRNA)
were added at a final concentration of 30nM. All transfections
were performed at the same time point, using siPORT Neo-FX
transfection reagent (Ambion), according to manufacturer’s
protocol. Cells from the stock flasks were trypsinised and counted.
The experiment was performed in duplicate.
RESULTS
In silico analysis of miRNA dysregulation in ovarian cancer
To elucidate the miRNA–KLK interaction in ovarian cancer, we
first analysed miRNA expression in ovarian cancer in silico.
Compiled data from eight published studies were used for analysis
(see Materials and Methods section). As shown in Table 1,
99 miRNAs were documented to have altered expression in ovarian
cancer; 46 up-regulated and 49 down-regulated, and 4 with
conflicting dysregulation patterns in 4 independent studies. Of
the 46 up-regulated miRNAs, 11 were reported in multiple studies.
Of the 49 down-regulated miRNAs, 13 were reported in multiple
studies. Not surprisingly, miR-21, one of the most widely studied
oncogenic miRNAs, was reported to be up-regulated in ovarian
cancer in five independent studies (Nam et al, 2008; Taylor and
Gercel-Taylor, 2008; Zhang et al, 2008; Boren et al, 2009; Resnick
et al, 2009). Mapping these miRNAs along the human genome, we
identified 10 miRNA clusters (with distances o50kb between two
adjacent miRNAs) located in 1p, 1q, 5q, 9q, 11q, 12p, 14q, 19q, and 22q.
Most of these clusters contain only two miRNAs. Members of the
same cluster could be under the same regulatory mechanisms
leading to co-dysregulation of these miRNAs, and subsequently
their KLK targets, in ovarian cancer. This may explain the parallel
dysregulation of many KLKs in ovarian cancer that have been
reported earlier.
In silico analysis of KLKs as miRNA targets in ovarian
cancer
The KLK expression in ovarian cancer was assessed by compiling
data from 14 published studies (see Materials and Methods
section). A total of 11 KLKs (KLK4-11, 13–15) were reported to be
Table 1 A list of all published miRNAs that were documented to be
dysregulated in ovarian cancer
a
miRNA # up # down miRNA # up # down
hsa-let-7a 1 hsa-miR-21 5
hsa-let-7b 1 hsa-miR-210 2
hsa-let-7d 1 hsa-miR-213 2
hsa-let-7e 1 hsa-miR-214 2 1
hsa-let-7f 1 hsa-miR-222 1
hsa-let-7i 1 hsa-miR-224 1
hsa-miR-100 2 hsa-miR-23a 1
hsa-miR-101-1 1 hsa-miR-23b 2
hsa-miR-103 1 hsa-miR-26a 1 1
hsa-miR-104 1 hsa-miR-26b 1
hsa-miR-106a 1 hsa-miR-27a 1
hsa-miR-10b 2 hsa-miR-299 1
hsa-miR-122a 1 hsa-miR-29a 1 1
hsa-miR-124a 1 hsa-miR-29c 1
hsa-miR-125a 2 hsa-miR-302c 1
hsa-miR-125b 4 hsa-miR-323 1
hsa-miR-126 2 hsa-miR-330 1
hsa-miR-127 2 hsa-miR-331 2
hsa-miR-128b 1 hsa-miR-337 1
hsa-miR-132 1 hsa-miR-339 1
hsa-miR-134 1 hsa-miR-340 1
hsa-miR-136 1 hsa-miR-34a 1
hsa-miR-140-5p 2 hsa-miR-34b 1
hsa-miR-141 3 hsa-miR-34c 1
hsa-miR-142-5p 1 hsa-miR-368 1
hsa-miR-143 2 hsa-miR-370 1
hsa-miR-145 4 hsa-miR-371 1
hsa-miR-149 1 hsa-miR-376a 1
hsa-miR-150 1 hsa-miR-376b 1
hsa-miR-152 1 hsa-miR-377 1
hsa-miR-154 1 hsa-miR-381 1
hsa-miR-155 2 hsa-miR-410 1
hsa-miR-16 1 hsa-miR-424 2
hsa-miR-181a 1 hsa-miR-431 1
hsa-miR-181b 1 hsa-miR-432 1
hsa-miR-182 1 hsa-miR-495 1
hsa-miR-184 1 has-miR-502 1
hsa-miR-185 1 hsa-miR-514 1
hsa-miR-191 1 hsa-miR-515-5p 1
hsa-miR-196a 1 hsa-miR-518c 1
hsa-miR-199a 2 hsa-miR-518c
a 1
hsa-miR-200a 3 hsa-miR-520f 1
hsa-miR-200b 2 hsa-miR-9 1
hsa-miR-200c 4 hsa-miR-92 1
hsa-miR-202 1 hsa-miR-93 2
hsa-miR-203 2 hsa-miR-98 1
hsa-miR-204 1 hsa-miR-99a 2
hsa-miR-205 1 hsa-miR-99b 1 1
has-miR-206 1 has-miR-516a 1
Has-miR-20a 1
Abbreviation: miRNA¼microRNA.
aData is compiled from eight published studies
(see Materials and Methods section).
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sdysregulated in ovarian cancer, mostly up-regulated. In addition to
their diagnostic usage, many have potential values as prognostic
markers, or predictive markers for treatment efficiency.
Target prediction analysis using three different programmes
showed that 62 miRNAs that are dysregulated in ovarian cancer
are predicted to target KLKs (Table 2). All KLKs, except KLK14,
were predicted to be targets for ovarian cancer-dysregulated
miRNAs. As reported earlier, multiple miRNAs were predicted to
target the same KLK and the same miRNA was predicted to target
multiple KLKs (Chow et al, 2008; Yousef, 2008). There were no
miRNAs that were predicted to target more than five KLKs.
We then examined the presence of correlated expression
patterns, that is down-regulation of the miRNA is associated with
KLK protein up-regulation and vice versa. Of the 125 occurrences
(Table 2), 61 (49%) of the dysregulated miRNAs correlated with
KLK expression in ovarian cancer.
Nine down-regulated miRNAs that target KLKs belong to the
large miRNA cluster in the long arm of chromosome 19, which
contains both the KLK locus and 48 miRNAs that can possibly
target KLKs, suggesting the possibility of these being co-regulated
in cancer. The KLKs 7, 9 10, 11, and 13 are the KLKs that are
predicted to be targets of the members of this miRNA cluster.
We then in silico tested the hypothesis that chromosomal
alterations (gains or losses) could be, at least partially, responsible
for miRNA dysregulation with subsequent alteration of KLK
protein levels in ovarian cancer. We correlated the expression
pattern of predicted KLK-targeting miRNAs that are dysregulated
in ovarian cancer with reported chromosomal aberration in the
same malignancy through publicly available databases (see
Materials and Methods section). Our results showed that 10 up-
regulated miRNAs were located in chromosomal hotspots that
frequently showed chromosomal gain in ovarian cancer. In
addition, 15 of the down-regulated miRNAs were located in
chromosomal hotspots that frequently showed chromosomal loss
in ovarian cancer, suggesting that the dysregulation of miRNAs in
ovarian cancer may be partially explained by chromosomal
aberrations.
Phylogenetic analysis
Sequence comparison of miRNAs among species was performed
through the University of California Santa Cruise Genome Browser
(Kent et al, 2002), using the Vertebrate Multiz Alignment and
PhastCons Conservation (multiple alignments of 28 vertebrate
species and two measures of evolutionary conservation). It was
found that let-7f, which has two copies in the human genome (on
chromosomes 9 and X) is highly conserved among mammalian
species, as was miR-224. However, miR-516a, which has two copies
on chromosome 19, is not conserved among mammalian species.
Many miRNAs within the human genome, particularly the earlier
discovered miRNAs are conserved among species. Phylogenetic
conservation implies an important conserved function during
evolution.
miRNA target validation: effect of miRNAs on KLK10
The KLK10, which is documented to be up-regulated in ovarian
cancer by many independent reports, was chosen for experimental
validation of in silico target prediction analyses. We tested the
hypothesis that multiple miRNAs can target the same KLK, and
examined the correlation between KLK protein suppression by
miRNAs on tumour cell proliferation. Prediction analysis from
different programmes showed that the 30UTR of KLK10 mRNA can
be targeted by multiple miRNAs, including let-7f, miR-224, and
miR-516a (Figure 1). These miRNAs are to be related to
oncogenesis and were also reported dysregulated in ovarian
cancer (Table 2). We experimentally validated the KLK10–miR
interactions using the pMIR–KLK10 construct. We chose to use
the OVCAR-3 ovarian cancer cell line as it has low endogenous
expression of miR-224 and no expression of let-7f (data not
shown). pMIR–KLK10 was transfected either alone or in
Table 2 miRNAs dysregulated in ovarian cancer and their predicted KLK
targets
KLK
miRNA 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Total
hsa-let-7a OO 2
hsa-let-7b OO O 3
hsa-let-7d O 1
hsa-let-7e O 1
hsa-let-7f OO 2
hsa-let-7i O 1
hsa-miR-103 OO 2
hsa-miR-106a OO 2
hsa-miR-10b OO 2
hsa-miR-122 OO O O 4
hsa-miR-125b O 1
hsa-miR-132 O 1
hsa-miR-140-5p OO O O 4
hsa-miR-141 O 1
hsa-miR-142-5p O 1
hsa-miR-143 OO O O O 5
hsa-miR-145 O 1
hsa-miR-149 OO O 3
hsa-miR-152 O 1
hsa-miR-181a OO 2
hsa-miR-181b OO 2
hsa-miR-196a O 1
hsa-miR-199a-5p OO 2
hsa-miR-200a O 1
hsa-miR-200b O 1
hsa-miR-200c O 1
hsa-miR-204 O 1
hsa-miR-205 OO 2
hsa-miR-206 OO O 3
hsa-miR-20a OO 2
hsa-miR-21 O 1
hsa-miR-210 O 1
hsa-miR-214 OO O O 4
hsa-miR-223 OO 2
hsa-miR-224 OO O 3
hsa-miR-26a OO 2
hsa-miR-26b OO 2
hsa-miR-302c O 1
hsa-miR-323-5p OO 2
hsa-miR-330-5p OO OOO 5
hsa-miR-331-5p OO 2
hsa-miR-337-3p O 1
hsa-miR-339-5p OO 2
hsa-miR-340 OO 2
hsa-miR-34a O 1
hsa-miR-34b O 1
hsa-miR-34c-5p O 1
hsa-miR-370 O 1
hsa-miR-371-5p OO 2
hsa-miR-376a OO O 3
hsa-miR-376b OO O 3
hsa-miR-377 OO O 3
hsa-miR-431 OO 2
hsa-miR-432 OOO O 4
hsa-miR-495 OO 2
hsa-miR-502-5p OO OO 4
hsa-miR-515-5p OO 2
hsa-miR-516a O 1
hsa-miR-520f OO 2
hsa-miR-9 OO 3
hsa-miR-93 OO 2
hsa-miR-98 O 1
Total 11 28 5 1 9 8 23 3 6 13 2 2 10 0 4 125
Abbreviation: miRNA¼microRNA; KLK¼kallikrein-related peptidase.
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scombination with the precursor molecule of let-7f in OVCAR-3
cells. Successful transfection was confirmed by qRT–PCR of the
corresponding miRNAs. Figure 2 shows that co-transfection of
let-7f and pMIR–KLK10 led to a significant suppression of the
luciferase signal. Such suppression in luciferase signal was not
evident when co-transfecting a random miRNA sequence control
and pMIR–KLK10 or let-7f and empty luciferase construct. The
luciferase signal was partially restored when co-transfecting
let-7f and its inhibitor sequence. These data confirm that let-7f
specifically targets the KLK10 30UTR.
To further validate miRNA target prediction and to confirm that
multiple miRNAs can target one KLK, we preformed the same
luciferase reporter assay using miR-224 in OVCAR-3 cells (Figure 3).
We observed a significant decrease in luciferase signal when we co-
transfected pMIR–KLK10 and miR-224 (Po0.001). When we
transfected pMIR–KLK10, mir-224 and anti-miR-224, there was
partial restoration of luciferase signal. These data together confirm
that let-7f and miR-224 can both target the 30UTR of KLK10.
We further validated our results by co-transfecting pMIR–
KLK10 with miR-224 and miR-516a in the LNCaP prostate cancer
cell line (Figure 4). Transfection of either of these miRNAs with
pMIR–KLK10 decreased luciferase signal confirming that miR-224
and miR-516a can target KLK10. Co-transfection of either of the
miRNAs with an empty vector did not result in depression of
luciferase signal.
Correlation between decreased KLK10 expression, miRNA
over-expression, and cell proliferation
To test the downstream biological effect of miRNAs on KLK10,
we measured ovarian cancer cell proliferation. We transfected
the ovarian cancer cell line OVCAR-5 with let-7f, miR-224, and
516a
1021 tggatcaata aagtcatacg ctccaactga tccagatgct acgctccagc tgatccagat 
516a
1081 gttatgctcc tgctgatcca gatgcccaga ggctccatcg tccatcctct tcctccccag 
1141 tcggctgaac tctccccttg tctgcactgt tcaaacctct gccgccctcc acacctctaa 
1201 acatctcccc tctcacctca ttcccccacc tatccccatt ctctgcctgt actgaagctg 
1261 aaatgcagga agtggtggca aaggtttatt ccagagaagc caggaagccg gtcatcaccc 
1321 agcctctgag agcagttact ggggtcaccc aacctgactt cctctgccac tccctgctgt 
224
1381 gtgactttgg gcaagccaag tgccctctct gaacctcagt ttcctcatct gcaaaatggg 
let-7f
1441 aacaatgacg tgcctacctc ttagacatgt tgtgaggaga ctatgatata acatgtgtat 
1501 gtaaatcttc atggtgattg tcatgtaagg cttaacacag tgggtggtga gttctgacta 
1561 aaggttacct gttgtcgtga tctgaccacg tcccggtgaa agcgtgtgtc cagggaagaa 
1621 gtgcacaggg tagcccccag tcccaacctt ccatccccaa cccttaggga tgatggaaga 
1681 atcattttcc tcaccctagt tccaagtccc aggaaacacc ttttaaccac ttccttctca 
1741 tctcccactg tttcccactt ctggttccac ccaacaccag ttcctccgag ctaggctggc 
1801 cctgagtcat tagcaccttc tctgccttca tgaggccact gaactcaagg gacctcacct 
1861 tgcttctatc ccagcctcta agaccagagg gccgaggggg tagtgaagat tgggaaaccc 
1921 ttgccacctc aactgcccag cttgtgccaa gaaacctccc tctgacattt aggggaaaat 
1981 ctttggtttg tctgttatta attggctgtg agattttcgt cctgaaaact tgggaggagg 
2041 aattgtttga ttctccctga aattggggga gggaagggga gttaatacac agaatccagg 
2101 taaggctaat agaagcttca gtgtccgctg ggtgtggtgg ctcacgcctg taatcctagc 
2161 actttgggag gccgaggaaa gcagatcatc tgaggtcagg tgttcgagac cagtctggcc 
2221 aaaatggtga aatcccatct ctactgaaaa tacaaaaact agccaggcat ggtggcaggc 
2281 acctataatc ccatctactt gggaggctga ggcagaagaa tcacttgaac ccggggggca 
516a
Figure 1 Partial sequence of the 30UTR region for KLK10 (transcript variant 1). Nucleotide positions refer to GenBank accession # NM_002776.
The position of the stop codon is circled. The miRNA predicted target sites are highlighted in grey with the targeting miRNA indicated above
each site.
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Figure 2 Effect of transfection of hsa-let-7f with pMIR–KLK10 on
luciferase activity. Cells were transfected with either pMIR–KLK10, pMIR–
KLK10 and has-let-7f precursor molecule, empty vector and has-let-7f
precursor molecule, pMIR–KLK10 and a random miR sequence, or the
pMIR–KLK10 with has-let-7f and the let-7f inhibitor. There was a decrease in
luciferase signal when cells were transfected with pMIR–KLK10 and let-7f.
The signal was partially restored when cells were co-transfected with pMIR–
KLK10, let-7f, and anti-let-7f. Luciferase signals were normalised with b-gal.
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smiR-516a (Figure 5). The miR-18a was included as a positive
control as it has been shown to have an oncogenic effect on cellular
proliferation. Transfection of any of the three miRNAs decreased
both KLK10 protein expression levels and the rate of cellular
proliferation when compared with the untransfected control cells.
Cells transfected with let-7f showed the greatest suppression in
both KLK10 expression and proliferation when compared with the
other miRNAs. The cells transfected with miR-224 or miR-516a
showed a similar trend with decreased KLK10 expression and cell
growth. We further examined whether let-7f could affect KLK10
expression in dose-dependent manner (Figure 6). We found that
the suppressor effect of let-7f miRNA on KLK10 protein expression
was in fact dose dependent, with lower KLK10 protein levels
associated with higher miRNA transfection concentrations.
We also compared KLK10 expression, at both the mRNA and
protein levels, before and after transfection with let-7f in OVCAR-3
cells, another ovarian caner cell line. We chose to use miR-17 as a
negative control, as it has partial sequence homology to let-7f and
is not predicted to target KLK10. When we transfected OVCAR-3
cells with let-7f alone, let-7f and its inhibitor, a random miR
sequence, and miR-17, we found that KLK10 protein expression
was significantly decreased in cells transfected with let-7f, but not
controls (Po0.001; Figure 7A). Transfection with let-7f and anti-
let-7f partially restored expression levels, indicating the specificity
of the miR–KLK10 interaction. There was a slight decrease in
KLK10 protein expression levels when cells were transfected with
the random miR and miR-17 that may be attributed to an indirect
effect by consequently targeting a protein known to be involved
with KLK10. The KLK10 mRNA expression levels showed only
slight decrease after miRNA transfection (Figure 7B). Decreased
mRNA expression after miRNA transfection has been reported
earlier (Lim et al, 2005; Yu et al, 2005; Nishi et al, 2009; Pan et al,
2009; Qu et al, 2009; Arora et al, 2010), and may be due to partial
degradation of the KLK10 transcript or other indirect effects.
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cells when miR-224 was co-transfected with pMIR–KLK10 (Po0.001).
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Figure 5 A bar graph showing the effect of miRNA transfection on
KLK10 protein level (dashed bars) and cell proliferation (grey bars) in
ovarian cancer cells. The transfection of any of the three miRNAs, let-7f,
miR-224, and miR-516a decreased both KLK10 protein levels and cellular
proliferation in the OVCAR-5 ovarian cancer cell line when compared with
untransfected controls. The transfection of miR-18 was used as positive
control, as it is known to have an oncogenic effect on cellular proliferation.
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Figure 6 A dose curve analysis of the effect of transfected let-7f
concentration on KLK10 protein level. Transfection of let-7f was found to
inhibit KLK10 protein production in a dose-dependent manner.
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sOur results suggest that over-expression of KLK10-targeting
miRNAs can lead to KLK10 protein down-regulation with
subsequent negative effect on tumour cell proliferation. The KLKs
represent downstream targets by which miRNAs can affect ovarian
cancer pathogenesis. They also show that therapeutic over-
expression of miRNAs that target KLK10 can lead to a reduction
in tumour cell growth and proliferation. We also showed, for the
first time, the presence of fine-tuning (quantitative) KLK protein
expression in ovarian cancer as the same KLK can be controlled by
multiple miRNAs.
DISCUSSION
Epithelial ovarian cancer is the most lethal gynaecologic malig-
nancy (Brucks, 1992). The high-mortality rate is ascribed to late
diagnosis, as epithelial ovarian tumours commonly lack early
warning symptoms. Furthermore, ovarian carcinomas often lack
definite precursor lesions, are quite heterogeneous, and the
molecular pathways underlying their progression are still elusive.
Thus, many attempts have been made to predict the biology of
ovarian tumours, to determine prognosis and develop new
treatment strategies. In this study, however, we provide the
first evidence of experimental validation that three different
miRNAs (let-7f, miR-224, and miR-516a) can target KLK10 (using
two distinct approaches) and subsequently have an effect on
ovarian cancer cell proliferation.
Our findings should be, however, interpreted with caution, as
the effect of let-7f (and other miRNAs) on cell proliferation can be
mediated through other targeted genes. We also provide a unique
association between miRNA dysregulation, KLK protein expres-
sion level, and ovarian cancer cell proliferation in a dose-
dependent manner. Together with published data about potential
effect of KLKs on ovarian cancer proliferation, these data strongly
suggest that KLK10 is a candidate downstream target by which
miRNA can affect ovarian cancer proliferation, although further
experimental validation is required. Regardless of this effect being
mediated through kallikreins, we provided strong evidence to
suggest the presence of a functional involvement of dysregulated
miRNAs on ovarian cancer proliferation.
Dysregulation of KLKs in ovarian cancer is well established in
the literature. There are several mechanisms that are hypothesised
for the dysregulation of KLKs in ovarian cancer. Many reports
have shown that many KLK mRNA transcripts are over-expressed
in cancer (Klokk et al, 2007; Mange et al, 2008; Pettus et al, 2009).
Hormonal control is another postulated mechanism (Yousef and
Diamandis, 1999; Shaw and Diamandis, 2008; Lai et al, 2009).
However, there are also reports that suggest that other regulatory
mechanism exists for KLK expression in cancers (Shan et al, 2007).
Our findings highlight the possibility that miRNAs represent a
potential regulatory mechanism for controlling kallikrein expres-
sion at the post-transcriptional level. The finding that many
miRNAs can target the same KLK and a single miRNA can target
more than one kallikrein suggest that miRNAs can exert a
‘quantitative’ control of kallikreins by using multiple targeting
sites in the kallikrein mRNA.
Many of the miRNAs that were shown to be dysregulated in
ovarian cancer and able to target KLKs were also shown to be
dysregulated in other malignancies. For example, hsa-let-7f was
found to be significantly up-regulated in breast cancer (Yan et al,
2008), and hsa-miR-224 was found to be significantly up-regulated
in prostate and thyroid cancer (Prueitt et al, 2008; Nikiforova et al,
2008). This might point out the presence of ‘common’ pathways
that are used by cancers in different organ tissues. It should be also
noted that these miRNAs have other predicted and experimentally
validated targets. For example, miR-224 is up-regulated in highly
invasion pancreatic ductal adenocarcinoma, and it is correlated
with the down-regulation of CD40, which it is predicted to target
(Mees et al, 2009). MiR-224 is also predicted to target apop-
tosis inhibitor-5 in hepatocellular carcinoma; it is found to be
significantly up-regulated in hepatocellular carcinoma and as a
result inhibits apoptosis and induces tumourigenesis (Wang et al,
2008). This indicates the presence of synergetic or harmonised
effects of miRNAs in cancer initiation and progression through
targeting multiple pathways.
The miRNA-based cancer gene therapy offers the theoretical
appeal of targeting multiple gene networks that are controlled by a
single, aberrantly expressed miRNA (Tong and Nemunaitis, 2008).
Reconstitution of tumour-suppressor miRNAs or sequence-
specific knockdown of oncogenic miRNAs has produced favour-
able anti-tumour outcomes in experimental models and are now
being tested for therapeutic applications in different cancers
(Garzon et al, 2006).
Our results show the potential usage of miRNAs or their
synthetic counterparts, small-interfering RNAs (siRNAs), to alter
KLK expression in cancer for therapeutic purposes. Reports have
shown that siRNA and RNAi were able to knockdown kallikrein
gene and protein expression (Bando et al, 2006; Klokk et al, 2007;
Shinoda et al, 2007). It should be noted, however, that the
endogenous or exogenous siRNAs and synthetic RNAi do not
function exactly similar to miRNAs (Yousef, 2008). Endogenous
siRNAs are derived from a double-stranded DNA precursors, and
have exact complementarity with their target sequence, whereas
miRNA form a local hairpin structure and the mature form is a
single-stranded molecule (Ambros et al, 2003). The negative
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Figure 7 The effect of let-7f on KLK10 protein and mRNA expression in
the OVCAR-3 cell line. (A) KLK10 protein expression was significantly
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complementarity to the 30UTR of the target, causing suppression of
protein translation through an RNA-induced silencing complex
pathway (Esquela-Kerscher and Slack, 2006).
Another potential interesting clinical application is the use of
KLK proteins as markers for miRNA treatment efficiency in the
future. Other means of inhibiting or inactivating KLK proteins in
cancer cells represent another alternative to block miRNA path-
ways in ovarian cancer. Blocking both KLKs and miRNAs might
augment the therapeutic effect.
Our target prediction analysis highlights the need for high
throughput target validation approaches. At the moment, there is
no ‘gold standard’ programme for miRNA target prediction
analysis, and the overall sensitivity rate is 65–68%. Our in silico
analysis showed a number of miRNA clusters within the genome.
The largest cluster is on chromosome 19, very close to the
kallikrein gene cluster. The two clusters can be simultaneous
targets to a control mechanism that affects this region, for example
locus control region or chromosomal insertion or deletions.
Our results were based on target prediction of the ‘classic’ form
of KLK genes. An added layer of complexity that should be
considered is the presence of many splice variants for kallikrein
genes, with some of them differ in their 30UTR (Kurlender et al,
2005). It is also important to examine whether these splice
variations can affect KLK protein expression by altering
miRNA-binding sites.
In conclusion, our combined bioinformatics and experimental
approach provides evidence that KLK10 is a downstream target for
multiple miRNAs in ovarian cancer, with a positive proliferative
effect on cancer cell proliferation. More detailed analyses are
needed for target validation of other KLKs and exploring the
possible involvement of miRNAs in controlling kallikrein gene
expression in ovarian cancer pathogenesis.
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